The Breathe Easy Study
The purpose of this study is to investigate a potential treatment for asthma, nasal polyps and urticaria (a rash triggered by an allergic reaction).
Asthma is common in Australia, affecting 1 in 8 adults and 1 in 10 children Asthma is a lung disorder where the tubes which carry air into the lungs become inflamed and constricted, resulting in shortness of breath, wheezing and coughing. It is commonly accompanied by allergic rhinitis which is caused by irritation and inflammation of the lining of the nose. Currently Omalizumab is an expensive treatment which limits the number of people who can benefit, having additional options should lower the cost of treatment making it more accessible.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!